An assessment of nucleic acid amplification testing for active mycobacterial infection



Download 12.08 Mb.
Page7/56
Date28.05.2018
Size12.08 Mb.
#51325
1   2   3   4   5   6   7   8   9   10   ...   56

Selection criteria


In general, studies were excluded if they:

  • did not address the research question;

  • focused on latent TB (as NAAT for latent TB has already been assessed);

  • did not provide information on the pre-specified target population (i.e. were focused on mycobacteria that cause Hansen’s disease (leprosy);

  • did not address one of the pre-specified outcomes and/or provided inadequate data on these outcomes;

  • were in a language other than English and were of a lower level of evidence than the included studies; or

  • did not have an appropriate study design.

If the same data were duplicated in multiple articles, only results from the most comprehensive or most recent article were included.

Specified a priori patient subgroups of particular interest in the analysis included patients with high and low pre-test probabilities of having TB and patients with HIV.


Search results


The PRISMA flowcharts are shown in Figure 6, Figure 7, Figure 8, Figure 9 and Figure 10. These outline the study selection process and number of papers considered at each stage of the SR (Liberati et al. 2009).

PRISMA flowcharts Source: Liberati et al. (2009)


Summary of the process used to identify and select studies investigating the use of NAAT to diagnose MTB (direct <a href=evidence, accuracy and change in management)" align="bottom" width="545" height="454" border="0">

Figure 6 Summary of the process used to identify and select studies investigating the use of NAAT to diagnose MTB (direct evidence, accuracy and change in management)



Download 12.08 Mb.

Share with your friends:
1   2   3   4   5   6   7   8   9   10   ...   56




The database is protected by copyright ©ininet.org 2024
send message

    Main page